Gemba, A Leading Enterprise Metaverse Platform, Secures $18 Million in Funding

Gemba, a virtual reality workforce training platform, is set to become the leading enterprise metaverse platform after securing $18 million in funding. The Series A funding round led by Parkway Venture Capital now leaves the platform valued at $60 million.

The platform specializes in Virtual Reality as a Service (VRaaS). Its proprietary VR technology combines software, content, and service. Thus, it is suitable for global enterprises that seek to train distributed workforces on different mediums. It allows for highly immersive learning programs, simulated factory walks, and live training events, all using a VR headset.

Nathan Robinson, CEO of Gemba, notes that the platform is a useful tool for transformational leaders. It helps them solve their biggest challenge: rolling out powerful and effective training at scale. And this happens in a compelling and cost-effective manner.

What The Funding Means for Gemba and the Metaverse

The funding has the CEO beaming, partly due to what it means for the future of the enterprise metaverse platform. Speaking during the announcement of the deal, he notes, “Gemba is at the forefront of a new enterprise metaverse. It’s virtual, hands-on, cost-efficient and the VR learning experience is incredible, but it’s the real-world ROI that’s been beyond expectations for our customers. Gemba is the right solution at the right time, and we are thrilled to welcome Parkway VC as partners in our joint mission to help people and organizations thrive in the next era of work.”

Jesse Coors-Blankenship, general partner and cofounder of Parkway Venture Capital, was equally excited. He notes that the venture is “excited to welcome Gemba to our growing portfolio of pioneering technologies of the future—at the intersection of AI, VR and simulation.”

Gemba has been around since 2013. Since then, it has managed to win the trust of over 4,000 executives. These head honchos work for over 675 different companies, including Pfizer, Dell, Philips, and Nike.